Leader
Urokinase in rheumatoid arthritis: causal or coincidental?
| The first 150 words of the full text of this article appear below. |
| |
Article |
|---|
The past 10 years have witnessed an increased
interest in the plasminogen activation system and its potential role(s)
in rheumatoid arthritis (RA). Two types of plasminogen activators
(PAs), urokinase (uPA) and tissue type PA (tPA), which are
structurally, immunologically, and genetically distinct, have been
identified in mammals. Both PAs are secreted as a single chain protein,
which in the case of uPA is essentially inactive (pro-uPA). Pro-uPA is
then converted by a single enzymatic cleavage into two chain active
enzyme. uPA and tPA are highly specific serine proteases catalysing the
conversion of plasminogen into plasmin.1 2 Plasminogen,
present in plasma and extracellular fluids, can bind to fibrin and also
to cell surface plasminogen receptors (PlnR), via its lysine binding
sites. The activity of PAs is controlled by natural inhibitors (PAls), which include PAI-1, the main PAI in the circulation, and PAI-2. In
addition, uPA activity is blocked by protease nexin 1 (PN-1). Another
This article has been cited by other articles:
-
Slot, O., Brünner, N., Locht, H., Oxholm, P., Stephens, R. W
(1999). Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis
58: 488-492
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
